3-V’s mission is to discover and develop drugs with broad-spectrum antiviral activity and low likelihood of resistance, using a new platform that allows the identification of host proteins as drug targets. Initially the Company will focus on the discovery and development of drugs against influenza virus, respiratory syncytial virus and rhinovirus.

3-V biosciences

Zurich, Switzerland
South San Francisco, CA

NGM uses a combination novel experimental approaches to exploit emerging human biology for the development of novel therapies for metabolic and cardiovascular disease. Initially, the Company will focus on the gastrointestinal endocrine system and stem cell biology with a view toward identifying novel factors implicated in type 2 diabetes.

NGM Biopharmaceuticals

South San Francisco, CA

Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science involving selective regulators that are critical to controlling gene expression. While the Company is initially focused on oncology, its technology platform will likely be applicable to other therapeutic areas, including autoimmune, inflammatory and neurological diseases.

Constellation Pharmaceuticals

Cambridge, MA

Immune Design is a new generation vaccine company built on emerging understanding of the role of dendritic cells in determining an effective immune response. The Company is employing improved adjuvants and novel technologies that target and control dendritic cells in an unprecedented manner. This approach could create an entirely new generation of prophylactic and therapeutic vaccines for infectious diseases and extend the coverage of current vaccines.

Immune Design Corp.

Seattle, WA